Document is current
Any future updates will be listed below
-
Authors
Enne, Virve I. https://orcid.org/0000-0002-0250-6377
Stirling, Susan
Barber, Julie A.
High, Juliet
Russell, Charlotte
Brealey, David
Dhesi, Zaneeta
Colles, Antony
Singh, Suveer
Parker, Robert
Peters, Mark
Cherian, Benny P.
Riley, Peter
Dryden, Matthew
Simpson, Ruan
Patel, Nehal
Cassidy, Jane
Martin, Daniel
Welters, Ingeborg D.
Page, Valerie
Kandil, Hala
Tudtud, Eleanor
Turner, David
Horne, Robert
O’Grady, Justin
Swart, Ann Marie
Livermore, David M.
Gant, Vanya
,
Turner-Bone, Ian
Wilding, Laura
Winmill, Helen
Tooke, Carly
Milner, Philip
Cuesta, Jeronimo
Aman, Zoran
Bull, Rhian
Carungcong, Jaime
da Costa, Patricia Correia
Moore, Luke
Mughal, Nabeela
Sonksen, Julian
Reid, Karen
Akinugbe, Olugbenga
O’Neill, Lauran
Karlikowski, Michael
North, Julie
Aramburo, Angela
Wang, Justin
Liyanage, Kamal
Tous, Laura
Tan, Jenny
Patel, Pooja
de Neef, Mark
Filipe, Helder
Mingo, Sara Garcia
Mack, Damian
Shaw, David
Williams, Karen
Waugh, Victoria
Ahmed, Naseem
Klein, Nigel
Ricciardi, Federico
Pandolfo, Alyssa
Stewart, Sarah-Jane
Shallcross, Laura
Bercades, Georgia
Hass, Ingrid
Smyth, Deborah
Gellamucho, Minnie
Dresser, Kerry
Wagner, Adam P.
Zhao, Xiaobei
Pipi, Giovanni
Dark, Paul
Charlett, Andre
Bennett, Susan
Aveyard, Paul
Masterton, Robert
Llewelyn, Martin
Saunders, Katie
Simpson, John
Reynolds, Rosy
Satta, Giovanni
Cherian, Benny
Dryden, Matthew
Riley, Peter
Livermore, David
Cooper, Elizabeth
Griffiths, Jennie
McWilliams, Margaret
Thompson, Patrick
Vicary, Penny
Wellings, Amander
Harmston, Rebecca
-
Funding
Funding for this research was provided by:
Programme Grants for Applied Research (RP-PG-0514-20018)
NIHR Imperial Biomedical Research Centre
UCLH Biomedical Research Centre
- License Information
-
More Information
Article History
Received: 8 August 2024
Accepted: 22 December 2024
First Online: 17 February 2025
Declarations
:
: DB reports payments for educational sessions from bioMérieux and Gilead and consultancy fees from Paion. VE reports consultancy and speaker fees from bioMérieux, personal fees from Alchemab Therapeutics, and in-kind contributions from Inflammatix Inc. JOG has reports personal fees and/or in-kind contributions and/or research funding from Oxford Nanopore Technologies (ONT), Simcere, Becton–Dickinson and Heraeus Medical. He is now an employee of ONT and holds shares in the company. VG reports speaker fees from bioMérieux and consultancy fees from Gilead, MSD, Pfizer and Shionogi. JH reports consultancy fees from bioMérieux. HK reports speaker fees from bioMérieux. DML reports personal fees from Adjutec, AstraZeneca, bioMérieux, Centauri, GenPax, GSK, Hikma, Merck/MSD, Nordic, Paion, Pfizer, Shionogi, Sumitovant, Summit, Thermofisher, Wockhardt and Zambon, He also reports shareholdings from GenPax, GSK, Merck, Oxford Nanopore and PerkinElmer/Revvity, comprising less than 10% of portfolio value. He also has nominated holdings in Arecor, Celadon Pharmaceuticals, Destiny Pharma, Eluceda Ltd., Genedrive, Poolbeg, Optibiotix, Probiotix Health, SkinBiotherapeutics, Trellus and Verici Dx (all of which have research/products pertinent to medical and diagnostic innovation) through Enterprise Investment Schemes but has no authority to trade these shares directly. All are outside the submitted work. All other authors declare no competing interests.
